# A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants

> **NCT02530060** · PHASE4 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 8 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC

## Key facts

- **NCT ID:** NCT02530060
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02530060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02530060, "A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02530060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*